Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCB-006
- Development stage
- Preclinical
- Lead developer
- TC BioPharm
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
TCB-006 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy being developed by TC BioPharm for the treatment of solid tumors, including ovarian cancer and triple-negative breast cancer. The therapy utilizes donor-derived gamma delta T cells that are genetically modified to express a CAR targeting the V-set domain containing T-cell activation inhibitor 1 (also known as B7-H4 or VTCN1). B7-H4 is a member of the B7 family of immune checkpoint molecules and is frequently overexpressed in various solid malignancies, where it inhibits T-cell mediated immune responses. By using gamma delta T cells via the proprietary ImmuniCAR platform, TCB-006 is designed as an "off-the-shelf" product intended to offer a safer profile with reduced risk of graft-versus-host disease (GvHD) and lower toxicity compared to conventional alpha-beta T-cell therapies. It is currently in the preclinical stage of development.
- Other names
- B7-H4 CAR-TB-7-H4 CAR-TB 7-H4 CAR-TVTCN1 CAR-TVTCN-1 CAR-TVTCN 1 CAR-TV-set domain containing T-cell activation inhibitor 1 CAR-T
02
Targets
VTCN1 (V-set domain containing T cell activation inhibitor 1)
Beyond the preview
Go deeper on TCB-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCB-006.